A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors

PHASE4CompletedINTERVENTIONAL
Enrollment

106

Participants

Timeline

Start Date

June 6, 2012

Primary Completion Date

March 19, 2016

Study Completion Date

July 26, 2018

Conditions
Well-differentiated Pancreatic Neuroendocrine Tumor
Interventions
DRUG

sunitinib

Sunitinib capsules will be given orally at continuous daily dosing with a starting dose of 37.5 mg. One cycle is equal to 28 days.

Trial Locations (26)

1088

Semmelweis Egyetem/II. Sz. Belgyogyaszati Klinika, Budapest

1200

Cliniques Universitaires Saint-Luc, Gastroenterologie, Brussels

2193

Wits Clinical Research, Johannesburg

3220

Barwon Health - University Hospital Geelong, Geelong

10032

Columbia University Medical Center, New York

20141

IEO Istituto Europeo di Oncologia, IRCCS, Milan

28050

Hospital Universitario Madrid Sanchinarro - Centro Integral Oncológico Clara Campal (CIOCC), Madrid

92118

Hôpital Beaujon, Clichy

92868

Univeristy of California, Orange

100029

China-Japan Friendship Hospital, Beijing

100071

307 Hospital of PLA, Beijing

100142

Beijing Cancer Hospital, Beijing

200032

Fudan University Shanghai Cancer Center, Shanghai

Zhongshan Hospital Fudan University, Shanghai

200347

Centrul de Oncologie Sf. Nectarie, Craiova

210002

Nanjing Bayi Hospital, Nanjing

400012

Tata Memorial Hospital, Mumbai

610041

West China Hospital of Sichuan University, Chengdu

656 53

Masarykuv onkologicky ustav, Brno

128 08

Fakultni poliklinika, Prague

Vseobecna Fakultni Nemocnice v Praze, Prague

812-8582

Kyushu University Hospital, Fukuoka

104-0045

National Cancer Center Hospital, Chuo-ku

0372

Oslo Universitetssykehus HF, Rikshospitalet, Oslo

022328

Institutul Clinic Fundeni, Centrul de Gastroenterologie si Hepatologie, Bucharest

833 10

Narodny Onkologicky ustav, Bratislava

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT01525550 - A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors | Biotech Hunter | Biotech Hunter